Prospective audit of a one‐centre combined nuchal translucency and triple test programme for the detection of trisomy 21

@article{Babbur2005ProspectiveAO,
  title={Prospective audit of a one‐centre combined nuchal translucency and triple test programme for the detection of trisomy 21},
  author={V. Babbur and Christoph C. Lees and Sandy F Goodburn and Nigel Morris and Andrew Breeze and Gerald A Hackett},
  journal={Prenatal Diagnosis},
  year={2005},
  volume={25}
}
To determine detection and false‐positive rates for trisomy 21 using two‐stage combined nuchal translucency (NT) and triple testing, whilst disclosing abnormal nuchal measurements at the scan. 
The NTplus method of screening for Down syndrome: achieving the 2010 targets?
The performance of pregnancy‐associated plasma protein‐A (PAPP‐A) as a first trimester trisomy 21 marker is hypothesized to improve below 11 weeks, whereas β‐human chorionic gonadotrophin (hCG) is
Community‐based screening for Down's Syndrome in the first trimester using ultrasound and maternal serum biochemistry
TLDR
Findings indicate that where FTS is accessible within routine antenatal care, a detection rate of 90% and low screen‐positive rate can be achieved using the FMF programme.
The utility assessment of Chinese pregnant women towards the birth of a baby with Down syndrome compared to a procedure‐related miscarriage
This study was performed to investigate the preferences of Chinese pregnant women for Down syndrome‐affected birth compared to invasive test‐related miscarriage, using the standard gamble approach,
Performance of Common Down Syndrome Screening Methods Used in India with Construction of an Indian Normogram for Nuchal Translucency/Crown–Rump Length Measurements in 14,337 Subjects
TLDR
A fixed NT cut-off point is not appropriate for the first trimester screening and the best sensitivity for assessing aneuploidies is achieved using the 95th centiles, but the 99th centile achieves higher specificity for gestational age.
Community‐based screening for Down syndrome in the first trimester using ultrasound and maternal serum biochemistry
TLDR
The data presented in this study do not illustrate the superiority of FTS over other methods in population screening for fetal aneuploidy but merely show that FTS is a very valuable screening method in comparison with others.
Obstetric and neonatal outcomes in severe fetal ventriculomegaly
TLDR
To determine the early outcome and the incidence of associated structural anomalies in pregnancies complicated by severe fetal ventriculomegaly (VM), a large number of women are selected for at-risk pregnancies.
First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.
TLDR
The accuracy of first and second trimester serum markers with and without first trimester ultrasound markers for the detection of Down's syndrome in the antenatal period is estimated and compared, as combinations of markers.
First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
TLDR
To estimate and compare the accuracy of first trimester ultrasound markers alone, and in combination with firsttrimester serum tests for the detection of Down's syndrome, and the impact of maternal age on test performance in subgroup analyses is investigated.
Biopsija korionskih resica u dijagnostici kromosomopatija
Biopsija korionskih resica (BKR) je invazivna metoda prenatalne dijagnostike koja se izvodi od navrsenog desetog do cetrnaestog tjedna. Tijekom zahv
Associations of vomiting and antiemetic use in pregnancy with levels of circulating GDF15 early in the second trimester: A nested case-control study
TLDR
Serum GFD15 concentrations were strongly positively correlated with hCG levels but were inversely correlated with maternal BMIs, a finding replicated in the NIPTeR Study, which supports the concept that GDF15 may be playing a pathogenic role in pregnancy-associated vomiting.
...
1
2
...

References

SHOWING 1-10 OF 22 REFERENCES
Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population
TLDR
To examine the effectiveness of nuchal translucency measurement in the detection of trisomy 21 in a low‐risk population, a large number of patients with low-risk pregnancies are surveyed.
Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low‐risk population
To evaluate screening for trisomy 21 in a low‐risk population utilizing a combination of nuchal translucency measurement in the first trimester and the triple test in the second trimester.
A comparison of the impact of screen‐positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: a pilot study
To compare the experiences of women who received a screen‐positive test result for Down syndrome after nuchal translucency screening or after biochemical screening in the first trimester of pregnancy
Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities
TLDR
Assessment of the relation between serum parameters and nuchal translucency in pregnancies affected by fetal aneuploidy in the first trimester finds no significant relationship.
Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome
It is uncertain whether first trimester nuchal translucency (NT) is more effective than the well‐established second trimester serum screening for fetal Down syndrome or whether their combination
Effect of first‐trimester nuchal translucency on second‐trimester maternal serum biochemical screening for Down's syndrome
  • B. Thilaganathan, A. Slack, N. Wathen
  • Medicine
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 1997
TLDR
The main outcome measures were abnormal fetal karyotype and the performance of screening tests.
The effect of nuchal translucency measurement on second‐trimester biochemical screening for Down's syndrome
TLDR
The results show that nuchal translucency measurement is not only an effective method of first‐trimester screening for Down's syndrome but also has implications for the likelihood ratio and positive predictive value of second-trimester biochemical screening.
Calculating correct Down's syndrome risks
TLDR
Women having both first trimester nuchal translucency and second trimester serum screening tests are likely to receive two different Down's syndrome risks, and how to calculate a valid combined risk is described.
Combined first trimester nuchal translucency and second trimester biochemical screening tests among normal pregnancies
TLDR
In normal pregnancies, NT and TT do not correlate and that their combined calculated risk in normal pregnancies is associated with a low screen‐positive rate of 2.0%.
A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A
To examine the potential impact of combining maternal age with fetal nuchal translucency thickness and maternal serum free β‐human chorionic gonadotropin (β‐hCG) and pregnancy‐associated plasma
...
1
2
3
...